ADDvise Group’s subsidiary MRC Systems has received an order from Rafarm, a leading pharmaceutical company based in Greece. The order is worth approximately EUR 2.6 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q4 2025. For further information, please … Read more
ADDvise Group’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm worth approximately SEK 72 million. The allocation decision involves the delivery of blood specimen collection equipment over a four-year period, commencing in May 2025. The allocation decision can be appealed up until December 20, 2024. For further information, please contact: Staffan … Read more
ADDvise is exploring the possibility of divesting its subsidiary AB Germa. Germa has shifted its focus primarily towards defense equipment, which falls outside of ADDvise’s core business within life science. ADDvise is therefore evaluating options to find a new owner who can further develop Germa and maximize its full potential within the defense segment. Since … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from Orbitworks, a company specialized in advanced technology, based in United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q2 2025. … Read more
To enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is designed to optimize the organization, establish a clearer strategic focus, and strengthen the foundation for both organic growth and acquisitions. Additionally, the structure facilitates valuable … Read more
The third quarter of 2024 showed strong order intake, +17%, and net revenue growth, +26%. Despite challenging comparative figures from 2023, especially in the pharmaceutical sector and rental of equipment for clinical trials, we showed robust development. Excluding these segments, we saw organic growth of 6% for January−September, reflecting the strength of our business. July–September … Read more
In accordance with the resolution at the Annual General Meeting 2022 of ADDvise Group, the nomination committee for the Annual General Meeting 2025 shall comprise of representatives of the three largest shareholders by votes, according to the shareholders’ register as of 30 June 2024 maintained by Euroclear Sweden, and of the chairman of the board … Read more
Media, investors and analysts are invited to attend a presentation of the interim report for the period July 1 – September 30, 2024. The presentation will take place on October 24, 2024, at 14:00 (CEST) / 08:00 AM (EST). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report in a webcast and … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from Medisept. The company is a medical device manufacturer for the healthcare industry based in Oran, Algeria. The order is worth approximately USD 1.3 million. The order involves design, paneling, and installation of a cleanroom and associated accessories for a new medical device manufacturing facility with … Read more
ADDvise Group’s subsidiary Germa has received an order from Saab AB (publ). The order has a total value of approximately SEK 32.5 million. The order relates to the delivery of equipment and related components. The deliveries will be separated and are expected to be made during 2025 as agreed between Germa and Saab. Payment will … Read more